Fig. 6: LncRNA-6195 represses HCC progression by inhibiting enzymatic activity of ENO1 | Cell Death & Disease

Fig. 6: LncRNA-6195 represses HCC progression by inhibiting enzymatic activity of ENO1

From: A novel lncRNA, TCONS_00006195, represses hepatocellular carcinoma progression by inhibiting enzymatic activity of ENO1

Fig. 6

a The expression level of ENO1 protein has no significant change when lncRNA-6195 was up/downregulated in cells. b ENO1 in HepG2 and L02 cells is mainly located in the cytoplasm (-c), and little is found in the nucleus (-n). The location and expression have no significant changes in lncRNA-6195 upregulated cells. c LncRNA-6195 is mainly located in the cytoplasm in HepG2, L02, and HepG2/6195 cells. d There is almost no ENO1 located on the cell membrane (-m) of HepG2 cells. e Enzyme activities of ENO1 is reduced in lncRNA-6195 overexpressed L02 and HepG2 cells. f, g Glucose consumption and lactate production are both reduced in lncRNA-6195-overexpressed L02 and HepG2 cells. h Enzyme activities of ENO1 is promoted in lncRNA-6195 downregulated HepG2/6195 cells. i, j Glucose consumption and lactate production are both increased in lncRNA-6195 downregulated HepG2/6195 cells. k Unlike pc-6195 which inhibits cell proliferation, pc-B has no significant effect on cell proliferation as assessed by the CCK-8 assay after transfected in HepG2 cells. l, m Compared with the control group (HepG2/ pc), glucose consumption and lactate production have no significant changes in lncRNA-6195 deletion mutant B-overexpressed HepG2 cells. (*P < 0.05, **P < 0.01, ***P < 0.001. Student’s t test. Data are represented as mean ± SD.)

Back to article page